SANSHO Receives Notice of Allowance for Patent on Treatment for Pulmonary Fibrosis (2ccPA)
June 16, 2026
SANSHO Co., Ltd. is pleased to announce
that the Japan Patent Office (JPO) has issued
a Notice of Allowance for a
patent application regarding "2ccPA (SSI-002)," our proprietary
drug
candidate currently under development for the treatment of pulmonary fibrosis.
1. Patent Overview
・ Title of Invention: Therapeutic Agent for Pulmonary Fibrosis
・ Patent Application No.: Tokugan 2022-565405
・ Date of Allowance: June 16, 2026
2. Future Outlook
Pulmonary fibrosis remains a disease with high unmet medical needs. We believe this milestone solidifies our intellectual property position and reflects the innovative value of
our development
pipeline.
SANSHO will continue to accelerate the
clinical development of 2ccPA to bring this therapeutic option to patients as
expeditiously as possible.
